Methods of treating alzheimer's disease by administration of protective protein/cathepsin A
AssigneeSt. Jude Children's Research Hospital
InventorsIda Annunziata, Alessandra D'Azzo
Life of this patent
Estimating the term…
Loading patent…
AssigneeSt. Jude Children's Research Hospital
InventorsIda Annunziata, Alessandra D'Azzo
Estimating the term…
Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile. As such, the level of lysosomal exocytosis activity and/or lysosomal sialidase activity is predictive of a diagnosis and/or prognosis of cancer, chemotherapy resistance or dementia associated with Alzheimer's disease.
A method of treating dementia associated with Alzheimer's disease in a human subject comprising administering to the human subject a therapeutically effective amount of a composition comprising a Protective Protein/Cathepsin A (PPCA) polypeptide.
Dependencies are inferred from the claim text.